Inhaled corticosteroids and the risk of a first exacerbation in COPD patients

de Melo M.N., Ernst P., Suissa S.

Source: Eur Respir J 2004; 23: 692-697
Journal Issue: May
Disease area: Airway diseases

Congress or journal article abstractPDF journal article, handout or slidesFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
de Melo M.N., Ernst P., Suissa S.. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients. Eur Respir J 2004; 23: 692-697

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003



Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006


Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006


Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009



Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Source: Eur Respir J 2003; 21: 260-266
Year: 2003



Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia
Source: Eur Respir J 2010; 36: 751-757
Year: 2010



The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007



Statin use is associated with reduced mortality in COPD
Source: Eur Respir J 2007; 29: 279-283
Year: 2007



Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: management
Year: 2010


Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005


Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006



Medication use in COPD: systematic review and meta-analysis
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007




Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia
Source: Eur Respir J 2011; 37: 36-41
Year: 2011



Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006



The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013


Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Modern treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 60S-66S
Year: 2001



What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002



The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001

Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005